Skip to main content

Progestin and breast cancer risk: a systematic review

Breast Cancer Research and Treatment volume 155, pages 3–12 (2016)Cite this article

Abstract

This systematic review summarizes research on the use of progestin and breast cancer risk. Although mainly used for contraception, progestin can help treat menstrual disorders, and benign breast, uterine, and ovarian diseases. Breast cancer is the leading site of new, non-skin, cancers in females in the United States, and possible factors that may modulate breast cancer risk need to be identified. ProQuest (Ann Arbor, MI) and PubMed-Medline (US National Library of Medicine, Bethesda MD, USA) databases were used to search for epidemiologic studies from 2000 to 2015 that examined the association between progestin and breast cancer. Search terms included epidemiologic studies + progesterone or progestin or progestogen or contraceptive or contraceptive agents +breast cancer or breast neoplasms. A total of six studies were included in the review. Five of the six studies reported no association between progestin-only formulations (including norethindrone oral contraceptives, depot medroxyprogesterone acetate, injectable, levonorgestrel system users, implantable and intrauterine devices) and breast cancer risk. Duration of use was examined in a few studies with heterogeneous results. Unlike studies of other oral contraceptives, studies indicate that progestin-only formulations do not increase the risk of breast cancer, although the literature is hampered by small sample sizes. Future research is needed to corroborate these findings, as further understanding of synthetic progesterone may initiate new prescription practices or guidelines for women’s health.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer Statistics, 2015. CA Cancer J Clin 65(1):5–29

    PubMed  Article  Google Scholar 

  2. Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast Cancer. J Clin Oncol 23(2):357–367

    PubMed  Article  Google Scholar 

  3. Murphy E (2011) Estrogen signaling and cardiovascular disease. Circ Res 109(6):687–696

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  4. Wells B, DiPiro J, Schwinghammer T, DiPiro C (2008) Pharmacotherapy handbook, seventh edition, 7th edn. McGraw-Hill Medical, New York

    Google Scholar 

  5. Adami H-O, Hunter D, Trichopoulos D (2008) Textbook of Cancer Epidemiology, vol 2. Oxford University Press, New York

    Book  Google Scholar 

  6. NCHS Data Briefs: Current Contraceptive Status Among Women Aged 15–44: United States, 2011–2013 [Internet]. 2014 Dec [cited 2015 Apr 4]. Report No.: 173. http://www.cdc.gov/nchs/data/databriefs/db173.htm

  7. Family Planning—United Nations Population Division Department of Economic and Social Affairs [Internet]. [cited 28 Mar 2015]. http://www.un.org/en/development/desa/population/theme/family-planning/index.shtml

  8. Löwy I, Weisz G (2005) French hormones: progestins and therapeutic variation in France. Soc Sci Med 60(11):2609–2622

    PubMed  Article  Google Scholar 

  9. Warren MP, Shantha S (1999) Uses of progesterone in clinical practice. Int J Fertil Womens Med 44(2):96–103

    PubMed  CAS  Google Scholar 

  10. Dumeaux V, Alsaker E, Lund E (2003) Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 105(6):844–850

    PubMed  CAS  Article  Google Scholar 

  11. Beaber EF, Malone KE, Tang M-TC, Barlow WE, Porter PL, Daling JR et al (2014) Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomark Prev 23(5):755–764

    CAS  Article  Google Scholar 

  12. Hormonal Contraceptives, Progestogens Only. In: Hormonal contraception and post-menopausal hormonal therapy: IARC monographs on the evaluation of carcinogenic risks to humans [Internet]. 1999. http://monographs.iarc.fr/ENG/Monographs/vol72/

  13. Pasqualini JR (2007) Progestins and breast cancer. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 23(Suppl 1):32–41

    CAS  Article  Google Scholar 

  14. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269

    PubMed  Article  Google Scholar 

  15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806–808

    Article  Google Scholar 

  16. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR et al (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346(26):2025–2032

    PubMed  CAS  Article  Google Scholar 

  17. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S et al (2000) Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151(4):396–403

    PubMed  CAS  Article  Google Scholar 

  18. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT et al (2004) Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception. 69(5):353–360

    PubMed  CAS  Article  Google Scholar 

  19. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A et al (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106(4):813–817

    PubMed  Article  Google Scholar 

  20. Fabre A, Fournier A, Mesrine S, Desreux J, Gompel A, Boutron-Ruault M-C et al (2007) Oral progestagens before menopause and breast cancer risk. Br J Cancer 96(5):841–844

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  21. Kumle M, Weiderpass E, Braaten T, Persson I, Adami H-O, Lund E (2002) Use of oral contraceptives and breast cancer risk: the Norwegian–Swedish women’s lifestyle and health cohort study. Cancer Epidemiol Biomark Prev 11(11):1375–1381

    CAS  Google Scholar 

  22. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: further results. Contraception 54(3 (Suppl)):1S–106S

    Google Scholar 

  23. Faculty of sexual & reproductive healthcare clinical guidance: Combined Hormonal Contraception Clinical Effectiveness Unit [Internet]. England: Faculty of Sexual and Reproductive Healthcare; pp 1–19. http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyPill09.pdf

  24. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI (2012) Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 7(345):e4944

    Article  Google Scholar 

  25. de Melo NR (2010) Estrogen-free oral hormonal contraception: benefits of the progestin-only pill. Womens Health 5:721

    Google Scholar 

  26. Faculty of Sexual & Reproductive Healthcare Clinical Guidance: Progestogen-only Pills Clinical Effectiveness Unit [Internet]. England: Faculty of Sexual and Reproductive Healthcare; pp 1–19. http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyPill09.pdf

  27. Sitruk-Ware R (2006) New progestagens for contraceptive use. Hum Reprod Update 12(2):169–178

    PubMed  CAS  Article  Google Scholar 

Download references

Acknowledgments

This publication was made possible in part by Grant Number T32-GM081740 from NIH-NIGMS. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIGMS or NIH.

Author information

Affiliations

  1. Department of Epidemiology and Biostatistics, University of South Carolina, 915 Greene Street, 2nd Floor #10, Columbia, SC, 29208, USA

    Marsha Samson, Nancy Porter, Olubunmi Orekoya, James R. Hebert, Swann Arp Adams & Susan E. Steck

  2. Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA

    Marsha Samson, Nancy Porter, James R. Hebert, Swann Arp Adams & Susan E. Steck

  3. Arnold School of Public Health, University of South Carolina, Columbia, SC, USA

    Marsha Samson, Nancy Porter, Olubunmi Orekoya, James R. Hebert & Swann Arp Adams

  4. College of Pharmacy, University of South Carolina, Columbia, SC, USA

    Charles L. Bennett

Authors
  1. Marsha Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olubunmi Orekoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James R. Hebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Swann Arp Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles L. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Susan E. Steck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marsha Samson.

Ethics declarations

Conflict of interest

None of the authors have conflicts of interest to disclose.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Ethical standards

Experiments comply with the current laws of the United States.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Samson, M., Porter, N., Orekoya, O. et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat 155, 3–12 (2016). https://doi.org/10.1007/s10549-015-3663-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3663-1

Keywords

  • Contraception
  • Risk
  • Pharmacoepidemiology
  • Breast cancer
  • Progestin
  • Progesterone
  • Progestogen